Structure

InChI Key KXNPVXPOPUZYGB-IOVMHBDKSA-N
Smiles CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1
InChI
InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C23H36N6O5S
Molecular Weight 508.65
AlogP 0.91
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 6.0
Number of Rotational Bond 9.0
Polar Surface Area 177.71
Molecular species ZWITTERION
Aromatic Rings 1.0
Heavy Atoms 35.0

Bioactivity

Mechanism of Action Action Reference
Thrombin inhibitor INHIBITOR DailyMed
Protein: Thrombin

Description: Prothrombin

Organism : Homo sapiens

P00734 ENSG00000180210
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Protease Serine protease Serine protease PA clan Serine protease S1A subfamily
- 4-1580 2 4-40 -
Assay Description Organism Bioactivity Reference
Concentration for doubling of partial thromboplastin time Homo sapiens 420.0 nM
Concentration for doubling of prothrombin time Homo sapiens 660.0 nM
Concentration for doubling of thrombin time Homo sapiens 62.0 nM
In vivo inhibition of thrombus formation in thromboplastin-induced deep vein thrombosis (DVT) rat model after iv bolus dosing at 1 mg/kg Rattus norvegicus 82.0 %
In vitro ability to inhibit the activity of human alpha Thrombin None 39.0 nM
In vitro inhibition of thrombin catalytic activity using s-2238 substrate at 10 uM was measured at rat after 3 min incubation with compound None 38.0 nM
In vitro inhibitory activity against hydrolysis of human alpha thrombin None 38.0 nM
Inhibitory activity against thrombin induced platelet aggregation None 52.0 nM
Inhibition of thrombin Homo sapiens 600.0 nM
In vitro binding affinity by measuring the inhibition of human thrombin None 20.0 nM
Inhibitory activity against thrombin. None 19.0 nM
In vitro inhibition constant (Ki) against human thrombin None 4.0 nM
Inhibitory activity against human thrombin (using Chromozym TH as the substrate) None 19.0 nM
Inhibition of human alpha-thrombin. Homo sapiens 10.0 nM
Inhibitory activity against thrombin None 550.0 nM
Inhibition against clot-associated thrombin. None 39.0 nM
Inhibitory activity against thrombin. None 9.6 nM
Inhibitory activity against bovine thrombin None 61.0 nM Inhibitory activity against bovine thrombin None 85.0 nM
Concentration required for 50% inhibition of thrombin induced platelet aggregation None 9.0 nM
Inhibitory activity against thrombin None 1.0 nM
Binding affinity determined against human alpha thrombin Homo sapiens 9.9 nM
Inhibitory activity against human thrombin Homo sapiens 331.0 nM
Inhibition of human thrombin Homo sapiens 5.4 nM
Inhibition of free thrombin (unknown origin) using S2238 as substrate Homo sapiens 10.6 nM
Inhibition of plasma clot-bound thrombin (unknown origin) using S2238 as substrate Homo sapiens 92.4 nM
Binding affinity to thrombin (unknown origin) by surface plasmon resonance analysis Homo sapiens 2.42 nM
Inhibition of human thrombin Homo sapiens 4.5 nM
Profibrinolytic activity in tissue factor-induced human plasma exposed to exogenous tissue plasminogen activator assessed as time needed to lyse 50% fibrin clot by turbidimetric assay Homo sapiens 600.0 nM
Inhibition of human thrombin using Ac-FVR-AMC as substrate incubated for 10 mins prior to substrate addition measured for 10 min by fluorescence assay Homo sapiens 9.46 nM
Inhibition of human thrombin using tosyl-glycyl-prolyl-arginine-4-nitranilide acetate as substrate preincubated for 10 mins by spectrophotometer analysis Homo sapiens 3.88 nM
Inhibition of human thrombin assessed as reduction in release of free nitroaniline using tosyl-glycyl-prolyl-arginine-4-nitranilide acetate as substrate preincubated for 10 mins followed by substrate addition by spectrophotometer Homo sapiens 11.7 nM
Inhibition of human plasma thrombin using chromogenix AB as substrate after 30 secs by UV-spectrophotometry Homo sapiens 40.0 nM
Inhibition of bovine plasma thrombin using chromogenix AB as substrate after 30 secs by UV-spectrophotometry Bos taurus 20.0 nM
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) Staphylococcus aureus subsp. aureus 5.54 %
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) Escherichia coli -1.85 %
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) Klebsiella pneumoniae 8.18 %
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) Pseudomonas aeruginosa 9.28 %
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 Acinetobacter baumannii 26.1 %
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 Candida albicans 4.39 %
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) Cryptococcus neoformans -2.44 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 5.68 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.08 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.08 %

Cross References

Resources Reference
ChEBI 94385
ChEMBL CHEMBL1166
DrugBank DB00278
DrugCentral 239
FDA SRS OCY3U280Y3
Guide to Pharmacology 6385
PubChem 92721
SureChEMBL SCHEMBL20567702
ZINC ZINC12466745